22 October 2025
22 October 2025
A meeting will be held to elect new board members following a disagreement between the board and its majority shareholder.
The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing challenges.
The facility is part of the company鈥檚 $70bn US R&D and manufacturing expansion pledge.
Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in colorectal cancer.
The results strengthen Hengrui鈥檚 dominance in the Chinese market, showing camrelizumab and rivoceranib's potential beyond advanced disease.
While anti-VEGF therapies remain the current standard of care, many DME patients experience suboptimal responses due to non-VEGF-related disease mechanisms.
40% of patients do not respond to or cannot tolerate standard first-line treatments, and Lyvdelzi provides a new option.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
